HCP Soundbytes Series – Evolving treatment landscape

The asthma and COPD treatment landscape is constantly evolving and will continue to evolve … hear from the experts

Over the last 50 years there have been a vast number of changes in the management of asthma and chronic obstructive pulmonary disease (COPD), and the landscape continues to evolve. One particular change has been the large increase in the number of different treatment options that are available, including inhaled corticosteroids, biologic therapies, and a plethora of different types of inhalers.1 Alongside this, there has also been an increased focus on supported self-management.2

Despite these advances, the burden of both asthma and COPD remains high.3 Therefore, there is still a need to increase the effectiveness of the way patients are using existing drugs, and to find more innovative ways of improving disease control.

Watch the video below to learn more from experts about the evolution of the treatment landscape in asthma and COPD.

Let’s Talk Respiratory is organised and funded by Teva Pharmaceuticals Europe B.V and intended for healthcare professionals only. Views provided by speakers are their own and not necessarily shared by Teva Pharmaceuticals. Information in the video/article may discuss drug classes where Teva have a product and products that are not authorised in all countries. Please consult local prescribing information.

Approval code:   RESP-TPE-NP-00384 Date of preparation:  May 2023


  1. European Medicines Agency. National registers of authorised medicines. Available online: (accessed May 2023)
  2. Pinnock H, et al. BMC Med 2017;15:64
  3. International Respiratory Coalition. LungFacts 2022. Available online: (accessed May 2023)